Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.

Annals of surgical oncology

Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM.
PMID: 34215956
Ann Surg Oncol. 2021 Jul 02; doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02.

PURPOSE: Image-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk...

Cite
Mansfield SA, McCarville MB, Lucas JT, et al. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2021;doi: 10.1245/s10434-021-10386-3.
Mansfield, S. A., McCarville, M. B., Lucas, J. T., Krasin, M. J., Federico, S. M., Santana, V. M., Furman, W. L., & Davidoff, A. M. (2021). Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Annals of surgical oncology, . https://doi.org/10.1245/s10434-021-10386-3
Mansfield, Sara A, et al. "Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma." Annals of surgical oncology vol. (2021). doi: https://doi.org/10.1245/s10434-021-10386-3
Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2021 Jul 02; doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02. PMID: 34215956.
Copy Download .nbib Format: NLM
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies.

Cancer

Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D.
PMID: 33598942
Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17.

BACKGROUND: A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies.METHODS: Patients...

Cite
Jeha S, Crews KR, Pei D, et al. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021;127(12):2074-2082doi: 10.1002/cncr.33465.
Jeha, S., Crews, K. R., Pei, D., Peyton, M., Panetta, J. C., Ribeiro, R. C., Zhao, X., Campbell, P., Metzger, M. L., Yang, J. J., Cheng, C., Pui, C. H., & Bhojwani, D. (2021). Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 127(12), 2074-2082. https://doi.org/10.1002/cncr.33465
Jeha, Sima, et al. "Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies." Cancer vol. 127,12 (2021): 2074-2082. doi: https://doi.org/10.1002/cncr.33465
Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17. PMID: 33598942; PMCID: PMC8710083.
Copy Download .nbib Format: NLM
Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins.

Biomedicines

Samarasinghe AE, Penkert RR, Hurwitz JL, Sealy RE, LeMessurier KS, Hammond C, Dubin PJ, Lew DB.
PMID: 33036262
Biomedicines. 2020 Oct 06;8(10). doi: 10.3390/biomedicines8100393.

Asthma affects over 8% of the pediatric population in the United States, and Memphis, Tennessee has been labeled an asthma capital. Plasma samples were analyzed for biomarker profiles from 95 children with severe asthma and 47 age-matched, hospitalized nonasthmatic...

Cite
Samarasinghe AE, Penkert RR, Hurwitz JL, et al. Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins. Biomedicines. 2020;8(10)doi: 10.3390/biomedicines8100393.
Samarasinghe, A. E., Penkert, R. R., Hurwitz, J. L., Sealy, R. E., LeMessurier, K. S., Hammond, C., Dubin, P. J., & Lew, D. B. (2020). Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins. Biomedicines, 8(10), . https://doi.org/10.3390/biomedicines8100393
Samarasinghe, Amali E, et al. "Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins." Biomedicines vol. 8,10 (2020). doi: https://doi.org/10.3390/biomedicines8100393
Samarasinghe AE, Penkert RR, Hurwitz JL, Sealy RE, LeMessurier KS, Hammond C, Dubin PJ, Lew DB. Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins. Biomedicines. 2020 Oct 06;8(10). doi: 10.3390/biomedicines8100393. PMID: 33036262; PMCID: PMC7600116.
Copy Download .nbib Format: NLM
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.

Cancer

Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE.
PMID: 34644414
Cancer. 2021 Oct 13; doi: 10.1002/cncr.33974. Epub 2021 Oct 13.

BACKGROUND: The objective of this study was to examine long-term outcomes among children newly diagnosed with cancer who were treated in dexrazoxane-containing clinical trials.METHODS: P9404 (acute lymphoblastic leukemia/lymphoma [ALL]), P9425 and P9426 (Hodgkin lymphoma), P9754 (osteosarcoma), and Dana-Farber Cancer...

Cite
Chow EJ, Aplenc R, Vrooman LM, et al. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2021;doi: 10.1002/cncr.33974.
Chow, E. J., Aplenc, R., Vrooman, L. M., Doody, D. R., Huang, Y. V., Aggarwal, S., Armenian, S. H., Baker, K. S., Bhatia, S., Constine, L. S., Freyer, D. R., Kopp, L. M., Leisenring, W. M., Asselin, B. L., Schwartz, C. L., & Lipshultz, S. E. (2021). Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer, . https://doi.org/10.1002/cncr.33974
Chow, Eric J, et al. "Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33974
Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2021 Oct 13; doi: 10.1002/cncr.33974. Epub 2021 Oct 13. PMID: 34644414.
Copy Download .nbib Format: NLM
Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.

Annals of surgical oncology

Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM.
PMID: 34215956
Ann Surg Oncol. 2022 Jan;29(1):661-670. doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02.

PURPOSE: Image-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk...

Cite
Mansfield SA, McCarville MB, Lucas JT, et al. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2021;29(1):661-670doi: 10.1245/s10434-021-10386-3.
Mansfield, S. A., McCarville, M. B., Lucas, J. T., Krasin, M. J., Federico, S. M., Santana, V. M., Furman, W. L., & Davidoff, A. M. (2022). Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Annals of surgical oncology, 29(1), 661-670. https://doi.org/10.1245/s10434-021-10386-3
Mansfield, Sara A, et al. "Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma." Annals of surgical oncology vol. 29,1 (2022): 661-670. doi: https://doi.org/10.1245/s10434-021-10386-3
Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2022 Jan;29(1):661-670. doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02. PMID: 34215956.
Copy Download .nbib Format: NLM
Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease.

Vaccines

Penkert RR, Chandramouli S, Dormitzer PR, Settembre EC, Sealy RE, Wong S, Young NS, Sun Y, Tang L, Cotton A, Dowdy J, Hayden RT, Hankins JS, Hurwitz JL.
PMID: 34451986
Vaccines (Basel). 2021 Aug 04;9(8). doi: 10.3390/vaccines9080860.

Children with sickle cell disease (SCD) suffer life-threatening transient aplastic crisis (TAC) when infected with parvovirus B19. In utero, infection of healthy fetuses may result in anemia, hydrops, and death. Unfortunately, although promising vaccine candidates exist, no product has...

Cite
Penkert RR, Chandramouli S, Dormitzer PR, et al. Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease. Vaccines (Basel). 2021;9(8)doi: 10.3390/vaccines9080860.
Penkert, R. R., Chandramouli, S., Dormitzer, P. R., Settembre, E. C., Sealy, R. E., Wong, S., Young, N. S., Sun, Y., Tang, L., Cotton, A., Dowdy, J., Hayden, R. T., Hankins, J. S., & Hurwitz, J. L. (2021). Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease. Vaccines, 9(8), . https://doi.org/10.3390/vaccines9080860
Penkert, Rhiannon R, et al. "Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease." Vaccines vol. 9,8 (2021). doi: https://doi.org/10.3390/vaccines9080860
Penkert RR, Chandramouli S, Dormitzer PR, Settembre EC, Sealy RE, Wong S, Young NS, Sun Y, Tang L, Cotton A, Dowdy J, Hayden RT, Hankins JS, Hurwitz JL. Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease. Vaccines (Basel). 2021 Aug 04;9(8). doi: 10.3390/vaccines9080860. PMID: 34451986; PMCID: PMC8402426.
Copy Download .nbib Format: NLM
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies.

Cancer

Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D.
PMID: 33598942
Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17.

BACKGROUND: A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies.METHODS: Patients...

Cite
Jeha S, Crews KR, Pei D, et al. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021;127(12):2074-2082doi: 10.1002/cncr.33465.
Jeha, S., Crews, K. R., Pei, D., Peyton, M., Panetta, J. C., Ribeiro, R. C., Zhao, X., Campbell, P., Metzger, M. L., Yang, J. J., Cheng, C., Pui, C. H., & Bhojwani, D. (2021). Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 127(12), 2074-2082. https://doi.org/10.1002/cncr.33465
Jeha, Sima, et al. "Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies." Cancer vol. 127,12 (2021): 2074-2082. doi: https://doi.org/10.1002/cncr.33465
Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17. PMID: 33598942; PMCID: PMC8710083.
Copy Download .nbib Format: NLM
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies.

Cancer

Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D.
PMID: 33598942
Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17.

BACKGROUND: A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies.METHODS: Patients...

Cite
Jeha S, Crews KR, Pei D, et al. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021;127(12):2074-2082doi: 10.1002/cncr.33465.
Jeha, S., Crews, K. R., Pei, D., Peyton, M., Panetta, J. C., Ribeiro, R. C., Zhao, X., Campbell, P., Metzger, M. L., Yang, J. J., Cheng, C., Pui, C. H., & Bhojwani, D. (2021). Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 127(12), 2074-2082. https://doi.org/10.1002/cncr.33465
Jeha, Sima, et al. "Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies." Cancer vol. 127,12 (2021): 2074-2082. doi: https://doi.org/10.1002/cncr.33465
Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer. 2021 Jun 15;127(12):2074-2082. doi: 10.1002/cncr.33465. Epub 2021 Feb 17. PMID: 33598942.
Copy Download .nbib Format: NLM
Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.

Annals of surgical oncology

Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM.
PMID: 34215956
Ann Surg Oncol. 2022 Jan;29(1):661-670. doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02.

PURPOSE: Image-defined risk factors (IDRFs) are associated with surgical risks in neuroblastoma. We sought to evaluate the impact of neoadjuvant therapy on IDRFs and associated ability to achieve gross total resection (GTR) of locoregional disease in patients with high-risk...

Cite
Mansfield SA, McCarville MB, Lucas JT, et al. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2021;29(1):661-670doi: 10.1245/s10434-021-10386-3.
Mansfield, S. A., McCarville, M. B., Lucas, J. T., Krasin, M. J., Federico, S. M., Santana, V. M., Furman, W. L., & Davidoff, A. M. (2022). Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Annals of surgical oncology, 29(1), 661-670. https://doi.org/10.1245/s10434-021-10386-3
Mansfield, Sara A, et al. "Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma." Annals of surgical oncology vol. 29,1 (2022): 661-670. doi: https://doi.org/10.1245/s10434-021-10386-3
Mansfield SA, McCarville MB, Lucas JT, Krasin MJ, Federico SM, Santana VM, Furman WL, Davidoff AM. Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma. Ann Surg Oncol. 2022 Jan;29(1):661-670. doi: 10.1245/s10434-021-10386-3. Epub 2021 Jul 02. PMID: 34215956.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries